Li Watsek
Stock Analyst at Cantor Fitzgerald
(2.51)
# 2,307
Out of 5,150 analysts
80
Total ratings
54.22%
Success rate
-1.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Li Watsek
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZLAB Zai Lab | Maintains: Overweight | $55 → $37 | $19.27 | +92.01% | 2 | Feb 27, 2026 | |
| TYRA Tyra Biosciences | Initiates: Overweight | n/a | $35.27 | - | 1 | Feb 24, 2026 | |
| AVBP ArriVent BioPharma | Initiates: Overweight | n/a | $26.56 | - | 1 | Dec 23, 2025 | |
| CMPX Compass Therapeutics | Initiates: Overweight | n/a | $5.69 | - | 1 | Dec 3, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $203 → $254 | $241.38 | +5.23% | 20 | Oct 13, 2025 | |
| CNTX Context Therapeutics | Initiates: Overweight | n/a | $2.60 | - | 1 | Oct 2, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | n/a | $34.68 | - | 3 | Sep 9, 2025 | |
| REPL Replimune Group | Upgrades: Overweight | n/a | $7.25 | - | 2 | Jul 30, 2025 | |
| KURA Kura Oncology | Reiterates: Overweight | n/a | $8.55 | - | 11 | Jun 26, 2025 | |
| ACRV Acrivon Therapeutics | Reiterates: Overweight | n/a | $1.69 | - | 2 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $6.20 | - | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $13.76 | - | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.19 | - | 7 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $22.68 | - | 4 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.63 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.04 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $17.84 | - | 5 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $5.54 | -45.85% | 4 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.45 | +244.83% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $38 | $2.73 | +1,291.94% | 1 | Aug 12, 2022 |
Zai Lab
Feb 27, 2026
Maintains: Overweight
Price Target: $55 → $37
Current: $19.27
Upside: +92.01%
Tyra Biosciences
Feb 24, 2026
Initiates: Overweight
Price Target: n/a
Current: $35.27
Upside: -
ArriVent BioPharma
Dec 23, 2025
Initiates: Overweight
Price Target: n/a
Current: $26.56
Upside: -
Compass Therapeutics
Dec 3, 2025
Initiates: Overweight
Price Target: n/a
Current: $5.69
Upside: -
Ascendis Pharma
Oct 13, 2025
Maintains: Overweight
Price Target: $203 → $254
Current: $241.38
Upside: +5.23%
Context Therapeutics
Oct 2, 2025
Initiates: Overweight
Price Target: n/a
Current: $2.60
Upside: -
IDEAYA Biosciences
Sep 9, 2025
Reiterates: Overweight
Price Target: n/a
Current: $34.68
Upside: -
Replimune Group
Jul 30, 2025
Upgrades: Overweight
Price Target: n/a
Current: $7.25
Upside: -
Kura Oncology
Jun 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $8.55
Upside: -
Acrivon Therapeutics
Mar 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.69
Upside: -
Mar 14, 2025
Initiates: Overweight
Price Target: n/a
Current: $6.20
Upside: -
Feb 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $13.76
Upside: -
Jan 24, 2025
Reiterates: Overweight
Price Target: n/a
Current: $2.19
Upside: -
Oct 7, 2024
Reiterates: Overweight
Price Target: n/a
Current: $22.68
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.63
Upside: -
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.04
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $17.84
Upside: -
Nov 22, 2023
Reiterates: Overweight
Price Target: $3
Current: $5.54
Upside: -45.85%
Sep 7, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.45
Upside: +244.83%
Aug 12, 2022
Maintains: Overweight
Price Target: $60 → $38
Current: $2.73
Upside: +1,291.94%